Lataa...
Osteoclast inhibitor treatment among men with metastatic castration-resistant prostate cancer
BACKGROUND: National Comprehensive Cancer Network guidelines recommend monthly osteoclast inhibitor treatment (OIT) in men with metastatic castration-resistant prostate cancer (mCRPC) to prevent skeletal related events (SREs). We assessed adherence to guidelines by quantifying treatment for SRE prev...
Tallennettuna:
| Julkaisussa: | Clin Oncol Res |
|---|---|
| Päätekijät: | , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2018
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6457685/ https://ncbi.nlm.nih.gov/pubmed/30984916 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.31487/j.COR.2018.03.001 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|